Ipsen
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.21 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.03 | 4 |
Strategy profile
Based on 15 disclosed transactions, Ipsen concentrates its licensing activity in Hematology, Oncology, and RareDisease. Ipsen pays a 1.28x premium over market median, with the strongest premiums in Oncology (1.21x). Their most common deal structure is Acquisition, with an average disclosed value of $967M. Most recent activity: 2026.
Premium by therapeutic area
How Ipsen pays relative to peer medians in each TA
Pipeline coverage & gaps
Ipsen has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 14 | $394M | $1.0B |
| License | 1 | $111M | $461M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | navtemadlin | Kartos Therapeutics | myelofibrosis | phase_3 | $450M | $1.8B |
| 2026 | Memo Therapeutics pipeline | Memo Therapeutics | — | unknown | — | $770M |
| 2026 | MDM2 blocker | Kartos | myelofibrosis | unknown | — | $1.8B |
| 2026 | Memo Therapeutics midstage monoclonal antibody | Memo Therapeutics | rare disease | phase_2 | — | $796M |
| 2026 | potravitug | Memo Therapeutics AG | BK polyomavirus / transplant nephrology | phase_2 | $224M | $784M |
| 2026 | Memo Therapeutics (company acquisition) | Memo Therapeutics | rare diseases | phase_2 | — | $800M |
| 2026 | navtemadlin (KRT-232) | Kartos Therapeutics | myelofibrosis | phase_2 | — | $1.8B |
| 2025 | ICT01 | ImCheck Therapeutics | acute myeloid leukemia | phase_2 | $406M | $1.2B |
| 2025 | ICT01 / IPN60340 | ImCheck Therapeutics | Immuno-oncology | phase_1 | $392M | $1.1B |
| 2025 | ICT01 | ImCheck Therapeutics | acute myeloid leukemia | phase_1 | $385M | $1.1B |
| 2024 | tovorafenib | Day One Biopharmaceuticals | pediatric low-grade glioma | approved | $111M | $461M |
| 2023 | Bylvay (odevixibat) | Albireo Pharma | pediatric cholestatic liver diseases (PFIC) | approved | $952M | $1.2B |
| 2022 | Tazverik (tazemetostat) | Epizyme | follicular lymphoma | approved | $247M | $417M |
| 2022 | Tazverik (tazemetostat), EZM0414, and preclinical programs | Epizyme, Inc. | follicular lymphoma | approved | $247M | $417M |
| 2022 | Tazemetostat | Epizyme | sarcoma | approved | $247M | $247M |
How this is computed
For each Ipsen deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 7 disclosed deal premiums vs. peer medians. Raw premium 1.279, clamped to [0.7, 1.5].